Trial Profile

A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Sorafenib (Primary)
Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms TIES

05 Jun 2010 Results of a multivariate analysis investigating the effects of imbalances in prognostic factors between the study arms on the primary endpoint were presented at ASCO 2010.
21 May 2010 Results will be presented at the 2010 ASCO Annual Meeting, according to an Onyx Pharmaceuticals media release.
22 Jul 2009 Primary endpoint 'Progression free survival' has been met, according to an Onyx Pharmaceuticals media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com